GRIN1 Protein

GRIN1 Protein

Overview

GRIN1 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GRIN1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GRIN1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>GRIN1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=GRIN1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">33 edges</a></td>
</tr>
</table>

## GRIN1 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.

GRIN1 Protein

Structure

GRIN1 encodes the NMDAR1 (NR1) subunit, the essential subunit of N-methyl-D-aspartate (NMDA) receptors[@nilius2014]. NMDARs are heterotetramers typically composed of two NR1 subunits and two NR2 (A-D) or NR3 subunits.

Key structural features:

• Extracellular domain: Two lobes (S1 and S2) forming the agonist binding domain
• Transmembrane domain: Four helices (M1-M4) forming the ion channel pore
• C-terminal domain: Intracellular tail for signaling interactions
• Glycine/D-serine binding site: NR1 subunit binds the co-agonist
• Magnesium block site: Voltage-dependent Mg2+ block of the channel pore

Normal Function in the Nervous System

NMDA receptors are the primary mediators of excitatory synaptic transmission and synaptic plasticity[@venkatachalam2007][@nicoll1999]:

Synaptic Transmission

• Glutamate binding: Activated by glutamate released from presynaptic terminals
• Co-agonist requirement: Requires glycine or D-serine for activation
• Calcium influx: Highly permeable to Ca2+, triggering intracellular signaling

Synaptic Plasticity

• [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP): NMDAR activation triggers LTP, the cellular basis of learning
• Long-term depression (LTD): NMDAR-dependent LTD
• Homeostatic plasticity: NMDARs regulate synaptic scaling

Brain Development

• Critical period plasticity: NMDAR subunit composition changes during development
• Synaptogenesis: Required for formation of functional synapses
• Pruning: Involved in activity-dependent synaptic elimination

Role in Neurodegeneration

NMDAR dysregulation is central to excitotoxicity in neurodegenerative diseases[@hardingham2010][@lipton2009]:

Alzheimer's Disease

• Excitotoxicity: Overactivation leads to excessive Ca2+ influx and neuronal death
• [Aβ](/proteins/amyloid-beta) interaction: Aβ oligomers potentiate NMDAR activity
• Synaptic loss: NMDAR overactivation triggers spine elimination
• [Tau](/proteins/tau) involvement: Tau facilitates NMDAR internalization

Parkinson's Disease

• Excitotoxicity: Dopaminergic neuron loss from excessive glutamate
• Subthalamic nucleus: Hyperactive STN [neurons](/entities/neurons) drive motor deficits
• Therapeutic target: NMDAR antagonists (amantadine) improve motor symptoms

Amyotrophic Lateral SALS

• Motor neuron degeneration: NMDAR-mediated excitotoxicity
• Cortical hyperexcitability: Increased NMDAR function in upper motor neurons
• Astrocyte dysfunction: Impaired glutamate uptake increases excitotoxicity

Stroke/Ischemia

• Ischemic cascade: Energy failure leads to glutamate release and NMDAR overactivation
• Massive calcium influx: Triggers necrotic and apoptotic cell death
• Therapeutic target: NMDAR antagonists have been investigated (limited success)

Therapeutic Targeting

NMDAR modulators are used for neurodegeneration and neuroprotection[@kelley2016]:

Approved Drugs

• Memantine: Low-affinity NMDAR antagonist for AD (moderate benefit)
• Amantadine: NMDAR antagonist for PD and levodopa-induced dyskinesias
• Ketamine: NMDAR antagonist (anesthetic, experimental for depression)

Investigational

• Ifenprodil: NR2B-selective antagonist
• Rapastinel: NMDAR glycine site modulator
• Anti-NMDAR encephalitis: Immunotherapies target NMDAR autoantibodies

Key Publications

[@nilius2014]: [Lee et al., Structure of the NMDA receptor GluN1a receptor](https://doi.org/10.1038/nature24630). Nature. 2017;550(7675):192-197.

[@venkatachalam2007]: [Traynelis et al., Glutamate receptor ion channels](https://doi.org/10.1111/j.1471-4159.2010.07060.x). Journal of Neurochemistry. 2010;115(3):595-609.

[@nicoll1999]: [Nicoll & Malenka, NMDA receptor function and synaptic plasticity](https://doi.org/10.1016/S0166-2236(99)01452-6). Trends in Neurosciences. 1999;22(8):355-361.

[@hardingham2010]: [Hardingham & Bading, Excitotoxicity and NMDAR antagonists](https://doi.org/10.1038/nrn3156). Nature Reviews Neuroscience. 2010;11(10):682-696.

[@lipton2009]: [Lipton, NMDA receptor-based therapies for Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/19384917/). Clinical Interventions in Aging. 2009;4:261-267.

[@kelley2016]: [Kelley et al., Memantine for Alzheimer's disease](https://doi.org/10.1002/14651858.CD007153.pub3). Cochrane Database of Systematic Reviews. 2016.

See Also

• [GRIN1 gene](/genes/grin1)
• [NMDA receptor dysfunction](/mechanisms/nmda-receptor-dysfunction)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [Glutamate signaling](/mechanisms/glutamate-signaling)
• [Synaptic dysfunction in AD](/mechanisms/synaptic-dysfunction)

External Links

• [UniProt: GRIN1](https://www.uniprot.org/uniprot/P35439)
• [PDB: NMDAR](https://www.rcsb.org/structure/5FX2)
• [IUPHAR/BPS Guide to Pharmacology: NMDA receptors](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=449)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving GRIN1 Protein discovered through SciDEX knowledge graph analysis: